关注
Dmytro Starenki
Dmytro Starenki
iRepertoire, Inc.
在 irepertoire.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
BRAFV600E Promotes Invasiveness of Thyroid Cancer Cells through Nuclear Factor κB Activation
I Palona, H Namba, N Mitsutake, D Starenki, A Podtcheko, I Sedliarou, ...
Endocrinology 147 (12), 5699-5707, 2006
1492006
Induction of thyroid cancer cell apoptosis by a novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin
DV Starenki, H Namba, VA Saenko, A Ohtsuru, S Maeda, K Umezawa, ...
Clinical cancer research 10 (20), 6821-6829, 2004
1192004
Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells
D Starenki, SK Hong, RV Lloyd, JI Park
Oncogene 34 (35), 4624-4634, 2015
882015
Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells
VM Pushkarev, DV Starenki, VA Saenko, H Namba, J Kurebayashi, ...
Endocrinology 145 (7), 3143-3152, 2004
852004
A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase
PK Wu, SK Hong, S Veeranki, M Karkhanis, D Starenki, JA Plaza, JI Park
Molecular and Cellular Biology, 2013
792013
Obesity diminishes response to PD-1-based immunotherapies in renal cancer
SK Boi, RM Orlandella, JT Gibson, WJ Turbitt, G Wald, L Thomas, ...
Journal for immunotherapy of cancer 8 (2), 2020
652020
Inhibition of nuclear factor-κB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells
D Starenki, H Namba, V Saenko, A Ohtsuru, S Yamashita
The Journal of Clinical Endocrinology & Metabolism 89 (1), 410-418, 2004
582004
Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo
D Starenki, JI Park
The Journal of Clinical Endocrinology & Metabolism 98 (4), 1529-1540, 2013
562013
Mortalin (GRP75/HSPA9) promotes survival and proliferation of thyroid carcinoma cells
D Starenki, N Sosonkina, SK Hong, RV Lloyd, JI Park
International journal of molecular sciences 20 (9), 2069, 2019
542019
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells
Z Meng, N Mitsutake, M Nakashima, D Starenki, M Matsuse, S Takakura, ...
Endocrinology 149 (11), 5357-5365, 2008
53*2008
The role of STAT3 in thyroid cancer
N Sosonkina, D Starenki, JI Park
Cancers 6 (1), 526-544, 2014
472014
Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer
DW Doo, S Meza-Perez, AI Londoño, WN Goldsberry, AA Katre, ...
Therapeutic advances in medical oncology 12, 1758835920913798, 2020
372020
Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells
A Podtcheko, A Ohtsuru, H Namba, V Saenko, D Starenki, I Palona, ...
Radiation Research 165 (1), 35-42, 2006
342006
Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability
PK Wu, SK Hong, D Starenki, K Oshima, H Shao, JE Gestwicki, S Tsai, ...
Oncogene 39 (21), 4257-4270, 2020
322020
Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1
TR McCaw, M Li, D Starenki, M Liu, SJ Cooper, RC Arend, A Forero, ...
Cancer Immunology, Immunotherapy 68, 2081-2094, 2019
322019
The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth
TR McCaw, M Li, D Starenki, SJ Cooper, M Liu, S Meza-Perez, RC Arend, ...
Cancer Immunology, Immunotherapy 68, 175-188, 2019
312019
Suppression of B-RafV600E melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone
SK Hong, D Starenki, PK Wu, JI Park
Cancer biology & therapy 18 (2), 106-114, 2017
272017
Effects of low and high concentrations of antitumour drug taxol in anaplastic thyroid cancer cells
VM Pushkarev, DV Starenki, VA Saenko, S Yamashita, OI Kovzun, ...
Experimental Oncology, 2009
272009
Pediatric medullary thyroid carcinoma
D Starenki, JI Park
Journal of pediatric oncology 3 (2), 29, 2015
262015
powerTCR: A model-based approach to comparative analysis of the clone size distribution of the T cell receptor repertoire
H Koch, D Starenki, SJ Cooper, RM Myers, Q Li
PLoS computational biology 14 (11), e1006571, 2018
222018
系统目前无法执行此操作,请稍后再试。
文章 1–20